AAM
JAZZ icon

Aberdeen Asset Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Aberdeen Asset Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-2,810
Closed -$341K – 749
2016
Q3 		$341K Buy
+2,810
New +$379K ﹤0.01% 717

Other funds holding JAZZ

PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CCM
Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Aberdeen Asset Management's JAZZ Position: Q4 2016 in Review

Aberdeen Asset Management sold out of Jazz Pharmaceuticals (JAZZ) in Q4 2016, closing a stake of 2,810 shares — an estimated $341K sold.

Aberdeen Asset Management first reported a position in JAZZ in Q3 2016 and held it in 1 quarter. The position peaked at $341K in Q3 2016. 295 funds tracked by Wall St. Rank hold JAZZ as of Q4 2016.

  • Aberdeen Asset Management reported no remaining Jazz Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
  • Aberdeen Asset Management sold 2,810 Jazz Pharmaceuticals shares in Q4 2016, an estimated $341K.
  • Aberdeen Asset Management first reported a position in Jazz Pharmaceuticals in Q3 2016 and held it in 1 quarter.
  • Aberdeen Asset Management's Jazz Pharmaceuticals position peaked at $341K in Q3 2016.
  • 295 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q4 2016.

Based on Aberdeen Asset Management's 13F filing for Q4 2016, filed 7 Feb 2017.